Onde in a to	Research and Development Quarterly		Date:3 <sup>rd</sup> Febru	Date:3 <sup>rd</sup> February 2022	
Subject:	Performance Report – Q3 2021/22  Alison Steel, Head of Research and Innovation				
Prepared By:	Elizabeth Gemmill, Research and Innovation Director				
Approved By: Presented By:	Alison Steel, Head of Research and Innovation				
Purpose					
To present the Research and Innovation Quarterly Decision					
Performance Report					
τ οποιπιαπός περοπ			Approval Assurance	X	
Update and assurance on performance KPI's and financial position			Assurance	^	
Update on recovery and growth of the SFH research portfolio and research priorities for 21/22			io		
Strategic Objectives					
To provide	To promote and	To maximise the	To continuously	To achieve	
outstanding	support health	potential of our	learn and	better value	
care	and wellbeing	workforce	improve		
			.,		
X	A	X	X	X	
Overall Level of					
	Assurance Significant	Sufficient	Limited	None	
Overall Level of					
Overall Level of Risks/Issues	Significant	Sufficient X	Limited		
Overall Level of	Significant  • Confirmed £	Sufficient X E752,652.04 EMCRN	Limited  N 2021/22 budget	None	
Overall Level of  Risks/Issues Financial	• Confirmed £ • Commercial	Sufficient X E752,652.04 EMCRN I income for re-inves	Limited  V 2021/22 budget tment £102,025.82	None in Q3 2021/22	
Overall Level of  Risks/Issues Financial  Patient Impact	• Confirmed £ • Commercia • 1049 partici	Sufficient X E752,652.04 EMCRN I income for re-inves pants recruited into	Limited  V 2021/22 budget  tment £102,025.82 iresearch studies, 64	None in Q3 2021/22 8 in to UPH studies	
Overall Level of  Risks/Issues Financial	Confirmed &     Commercial     1049 partici     Collaboration	Sufficient X E752,652.04 EMCRN I income for re-inves	Limited  N 2021/22 budget tment £102,025.82 research studies, 64 Trent University to su	None in Q3 2021/22 8 in to UPH studies apport development	
Overall Level of  Risks/Issues Financial  Patient Impact	Confirmed £     Commercial     1049 partici     Collaboration of clinical acceptance.	Sufficient X E752,652.04 EMCRN I income for re-investigates recruited into the month of the mont	Limited  1 2021/22 budget  1 2021/22 budget  1 2025.82 in  2 research studies, 64  2 rent University to su  3 research exposure	in Q3 2021/22 8 in to UPH studies apport development for clinical staff	
Risks/Issues Financial  Patient Impact Staff Impact Services	Confirmed £     Commercial     1049 partici     Collaboration of clinical access.      Support Clirical	Sufficient X E752,652.04 EMCRN I income for re-invest pants recruited into an with Nottingham Total Divisions with recruited Divisions with Recrui	Limited  N 2021/22 budget tment £102,025.82 research studies, 64 Trent University to su tresearch exposure esearch engagemen	None in Q3 2021/22 8 in to UPH studies upport development for clinical staff	
Risks/Issues Financial Patient Impact Staff Impact	Confirmed £     Commercial     1049 partici     Collaboration of clinical accommendation of clini	Sufficient X E752,652.04 EMCRN I income for re-invest pants recruited into on with Nottingham Total Divisions with recongreputation for re	Limited  N 2021/22 budget tment £102,025.82 research studies, 64 Trent University to su the research exposure esearch engagement search delivery enh	None in Q3 2021/22 8 in to UPH studies upport development for clinical staff	
Risks/Issues Financial  Patient Impact Staff Impact Services	Confirmed £     Commercial     1049 partici     Collaboration of clinical actions a street of the street of t	Sufficient X 2752,652.04 EMCRN I income for re-investigation with Nottingham Total Divisions with recongreputation for reJPH delivered at SFI	Limited  V 2021/22 budget  Itment £102,025.82 if research studies, 64  Trent University to sure research exposure research engagement research delivery enhance	None in Q3 2021/22 8 in to UPH studies apport development for clinical staff anced by the	
Risks/Issues Financial  Patient Impact Staff Impact Services	Confirmed £     Commercial     1049 partici     Collaboratio of clinical accommercial     Support Clinical accommercial     Retain a strubreadth of Leading the	Sufficient X E752,652.04 EMCRN I income for re-invest pants recruited into pants recruited in	Limited N 2021/22 budget tment £102,025.82 research studies, 64 rent University to su research exposure esearch engagement search delivery enh H ion with GP practise	None in Q3 2021/22 8 in to UPH studies apport development for clinical staff anced by the s to increase	
Risks/Issues Financial  Patient Impact Staff Impact Services	Confirmed £     Commercial     1049 partici     Collaboration of clinical according to the control of the	Sufficient X 2752,652.04 EMCRN I income for re-investigation with Nottingham Total Divisions with recongreputation for reJPH delivered at SFI	Limited  N 2021/22 budget tment £102,025.82 research studies, 64 rent University to su research exposure esearch engagement esearch delivery enh H ion with GP practise field and Ashfield, N	None  in Q3 2021/22 8 in to UPH studies apport development for clinical staff  anced by the s to increase lewark and	
Risks/Issues Financial  Patient Impact Staff Impact  Services Reputational	Confirmed £     Commercial     1049 partici     Collaboration of clinical actions of clinical actions and the commercial of the commercial of clinical actions of	Sufficient X E752,652.04 EMCRN I income for re-invest pants recruited into on with Nottingham Total Divisions with recongreputation for reJPH delivered at SFI way with collaboration proportunities in Mans Secondment placement.	Limited N 2021/22 budget tment £102,025.82 research studies, 64 Trent University to sure research exposure research engagement research delivery enh H rion with GP practise field and Ashfield, N rent to commence Fe	None  in Q3 2021/22 8 in to UPH studies apport development for clinical staff  anced by the s to increase lewark and	
Risks/Issues Financial  Patient Impact Staff Impact  Services Reputational	Confirmed £     Commercial     1049 partici     Collaboration of clinical according to the control of the	Sufficient X E752,652.04 EMCRN I income for re-invest pants recruited into on with Nottingham Total Divisions with recongreputation for reJPH delivered at SFI way with collaboration proportunities in Mans Secondment placement.	Limited N 2021/22 budget tment £102,025.82 research studies, 64 Trent University to sure research exposure research engagement research delivery enh H rion with GP practise field and Ashfield, N rent to commence Fe	None  in Q3 2021/22 8 in to UPH studies apport development for clinical staff  anced by the s to increase lewark and	
Risks/Issues Financial  Patient Impact Staff Impact  Services Reputational	Confirmed £     Commercial     1049 partici     Collaboration of clinical actions of clinical actions and the commercial of the commercial of clinical actions of	Sufficient X E752,652.04 EMCRN I income for re-invest pants recruited into on with Nottingham Total Divisions with recongreputation for reJPH delivered at SFI way with collaboration proportunities in Mans Secondment placement.	Limited N 2021/22 budget tment £102,025.82 research studies, 64 Trent University to sure research exposure research engagement research delivery enh H rion with GP practise field and Ashfield, N rent to commence Fe	None  in Q3 2021/22 8 in to UPH studies apport development for clinical staff  anced by the s to increase lewark and	

## **Executive Summary Performance Metrics**

## • 1049 participants recruited into research studies compared to 2468 Q3 20/21, 62 studies on the SFH portfolio

- Confirmed £752,652.04 EMCRN 2021/22 budget.
- Commercial income at £102,025.82

## **Research Priorities**

- 1. Develop a balanced R&I function that can deliver Covid-19 Research alongside a healthy portfolio of non UPH studies.
- 2. Work with and support Clinical Divisions with research engagement

- 3. Further develop partnership with Nottingham Trent University to support development of clinical academic careers and research skills for clinical staff relevant to their role; including training, mentoring and research idea development
- 4. Work closely with the transformation team to develop a mechanism to capture and cultivate innovation with a focus on commercialisation and intellectual property
- 5. Develop an R&I plan across the system SFH representation on the ICS R&I Executive Group as key contributors to the planning and coordination of services, ensuring equal access to research across the region.
- 6. Focus on working in partnership with GP practices in Mansfield and Ashfield, Newark and Sherwood. PANORAMIC study in set up that will enable us to work collaboratively.
- 7. Creating a research environment at SFH which can deliver digitally enabled trials
- 8. Developing the Clinical Research Facility.